Granite Point Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Granite Point Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-43,000	Closed	-$374K	–	146
2018 Q1	$374K	Sell	43,000 -57,000	-57%	-$615K	0.04%	87
2017 Q4	$1.25M	Sell	100,000 -100,000	-50%	-$1.15M	0.12%	47
2017 Q3	$1.67M	Buy	200,000 +64,800	+48%	+$685K	0.35%	38
2017 Q2	$2.29M	Buy	135,200 +36,200	+37%	+$720K	0.57%	30
2017 Q1	$1.99M	Buy	+99,000	New	+$1.97M	0.59%	26

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FTIOP

Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granite Point Capital Management's ZYNE Position: Q2 2018 in Review

Granite Point Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2018, closing a stake of 43,000 shares — an estimated $374K sold.

Granite Point Capital Management first reported a position in ZYNE in Q1 2017 and held it in 5 quarters. The position peaked at $2.29M in Q2 2017. 59 funds tracked by Wall St. Rank hold ZYNE as of Q2 2018.

Granite Point Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2018 after selling out during the quarter.
Granite Point Capital Management sold 43,000 Zynerba Pharmaceuticals, Inc shares in Q2 2018, an estimated $374K.
Granite Point Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 5 quarters.
Granite Point Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $2.29M in Q2 2017.
59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2018.

Based on Granite Point Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.